H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
Closeup of a biopharmaceutical worker holding a beaker of white liquid in a laboratory.
The company released additional analysis from phase 2a RIVER trial suggesting a more de-risked path to approval as compared to the current market expectations, said the analyst. He believes that the company can achieve over $1 billion in revenue from the drug's treatment of refractory chronic cough alone. Moreover, the Idiopathic Pulmonary Fibrosis chronic cough could be another significant revenue stream for Trevi Therapeutics, Inc. (NASDAQ:TRVI).
The current market capitalization of the company is around $627 million which is undervalued considering the strong results from the RIVER trial, said the analyst. Livna expects Haduvio to become a best-in-class for both Idiopathic Pulmonary Fibrosis and refractory chronic cough.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, which is an investigational therapy aimed at treating chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
While we acknowledge the potential of TRVI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRVI and that has 100x upside potential, check out our report about the .
READ NEXT: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Cisco (CSCO) Price Target Lowered to $64 Despite Strong AI Narrative
Cisco Systems, Inc. (NASDAQ:CSCO) is one of the On August 14, Piper Sandler analyst James Fish lowered the price target on the stock to $64.00 (from $70.00) while maintaining a Neutral rating. Fish noted how Cisco's quarterly results were roughly in-line, and that FY26 guide came in below what bulls were hoping for. This is raising questions about 'peak growth x peak multiple' being already seen, with second half of 2026 guide implying less than 5%. Stock market data on a laptop screen. Photo by Alesia Kozik on Pexels However, the firm believes that the narrative for Cisco remains unscathed owing to artificial intelligence. 'However, the narrative here remains unscathed, as Cisco will see the ~$1B AI orders in F2H25 flow into FY26 revenue, further AI-infrastructure spend (including across customer-bases), campus refresh, datacenter refresh & modernization, growing Enterprise & Neoclouds traction, and Splunk cross-sell and cost-synergies. FY26 guide looks about how we anticipated and realistic, particularly for an incoming CFO. The debate from here will be sustainability, and while we remain optimistic around the narrative across multiple fronts, even an upside numbers scenario is already embedded in the stock at these levels. Reit. Neutral, PT to $70.' While we acknowledge the potential of CSCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
24 minutes ago
- Forbes
Zoom Communications: Sell ZM Stock Now?
Zoom Communications (NASDAQ: ZM) is slated to report its Q2 results on Thursday, August 21, 2025. Over the last five years, Zoom's stock posted a negative one-day move after earnings 74% of the time. Those negative moves had a median of -7.7% and reached a maximum of -16.7%. For event-driven traders, this history is informative, though the actual reaction will hinge on how results stack up against consensus and broader expectations. Two approaches that may leverage this dataset are: Current consensus forecasts call for earnings per share of $1.38 on revenue of $1.2 billion for the quarter, versus $1.39 EPS on $1.16 billion in revenue in the same quarter last year. From a fundamentals perspective, Zoom's market capitalization stands at $22 billion. Over the trailing twelve months, the company generated $4.7 billion in revenue, delivered operating profit of $852 million, and recorded net income of $1.0 billion. Also, see Buy or Sell Zoom Stock. If you prefer pursuing upside with lower single-stock volatility, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and produced returns of over 91% since inception. Also, see – Buy IBM Stock At $240? See earnings reaction history of all stocks Zoom Communications' Historical Odds Of Positive Post-Earnings Return Key notes on one-day (1D) post-earnings moves: Additional detail on 5-Day (5D) and 21-Day (21D) post-earnings returns, plus summary statistics, appears in the table below. Correlation Between 1D, 5D, and 21D Historical Returns A relatively lower-risk tactic (though not useful if correlations are weak) is to identify the strongest link between short- and medium-term returns after earnings, then trade accordingly. For example, if 1D and 5D are most correlated, a positive 1D reaction could support a short-term 'long' stance for the next 5 days. Here is correlation data based on both a 5-year window and a more recent 3-year window. Also, see – Buy or Fear ZM Stock? Is There Any Correlation With Peer Earnings? Peer performance can sometimes shape post-earnings reactions, with pricing-in even occurring ahead of the release. Below is historical context comparing Zoom Communications' post-earnings 1D returns with those of peers that reported shortly before Zoom. Learn more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P MidCap, and Russell 2000), delivering strong returns for investors. If you want upside with a smoother ride than an individual stock like Zoom Communications, consider the High Quality portfolio, which has outperformed the S&P and returned >91% since inception.
Associated Press
41 minutes ago
- Associated Press
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA - August 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ('Replimune') ( NASDAQ: REPL ) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is September 22, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Replimune losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Replimune overstated the trial's prospects for the company's lead product candidate; and (2) as a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. THE LEAD PLAINTIFF PROCESS: Replimune investors may, no later than September 22, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Replimune investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
